Skip to content
value.today

Arena Pharmaceuticals Inc.

Total raised
$187 M
2 rounds on record
Latest round
$36 M
Jun 2010
First round on record
Jul 2009
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Arena Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2010$36 MNo. 2$10 to $50 million

Arena Pharmaceuticals Inc.: Raise no. 2, Jun 2010

Investors in this round

6 investors had bought by the notice of Jun 21, 2010: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$36 M of $36 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dominic P. Behan · Executive Officer, Director
  • Jack Lief · Executive Officer, Director
  • K.A. Ajit-Simh · Executive Officer
  • Robert E. Hoffman · Executive Officer
  • Steven W. Spector · Executive Officer
  • William R. Shanahan, Jr. · Executive Officer
  • Christine A. White · Director
  • Donald D. Belcher · Director
  • Harry F. Hixson, Jr. · Director
  • J. Clayburn La Force, Jr. · Director
  • Phillip M. Schneider · Director
  • Randall E. Woods · Director
  • Scott H. Bice · Director
  • Tina S. Nova · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert E. Hoffman, Vp, finance and cfo. Source: SEC Form D, newest notice filed Jun 21, 2010. Read the notice at the SEC.

equitySEC
Jul 2009$152 MNo. 1$50 to $250 million

Arena Pharmaceuticals Inc.: Raise no. 1, Jul 2009

Investors in this round

6 investors had bought by the notice of Jul 21, 2009: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$152 M of $152 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dominic P. Behan · Executive Officer, Director
  • Jack Lief · Executive Officer, Director
  • K.A. Ajit-Simh · Executive Officer
  • Robert E. Hoffman · Executive Officer
  • Steven W. Spector · Executive Officer
  • William R. Shanahan, Jr. · Executive Officer
  • Christine A. White · Director
  • Donald D. Belcher · Director
  • Harry F. Hixson, Jr. · Director
  • J. Clayburn La Force, Jr. · Director
  • Phillip M. Schneider · Director
  • Randall E. Woods · Director
  • Scott H. Bice · Director
  • Tina S. Nova · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • PIPER JAFFRAY & CO. (CRD 665) · broker-dealer PIPER JAFFRAY & CO. (CRD 665) · Minneapolis, MnSold in no state named

Remarks in the notice

  • On the amounts: “INCLUDES AMOUNTS RECEIVABLE BY THE COMPANY UPON THE EXERCISE OF WARRANTS TO PURCHASE COMMON STOCK (ASSUMING NO NET-ISSUE EXERCISE).”

Signed by Robert E. Hoffman, Vp, finance and cfo. Source: SEC Form D, newest notice filed Jul 21, 2009. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Arena Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2010).

    SEC Form D · Jun 2010

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2010

That is all the official record says: Arena Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: the address on record now leads to another company's site.

Investors#

No investor of Arena Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 6 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Arena Pharmaceuticals Inc.
NameRoleNamed in
Dominic P. BehanExecutive officerJun 2010
Jack LiefExecutive officerJun 2010
K.A. Ajit-SimhExecutive officerJun 2010
Robert E. HoffmanExecutive officerJun 2010
Steven W. SpectorExecutive officerJun 2010
William R. Shanahan, Jr.Executive officerJun 2010
Christine A. WhiteDirectorJun 2010
Dominic P. BehanDirectorJun 2010
Donald D. BelcherDirectorJun 2010
Harry F. Hixson, Jr.DirectorJun 2010
J. Clayburn La Force, Jr.DirectorJun 2010
Jack LiefDirectorJun 2010
Phillip M. SchneiderDirectorJun 2010
Randall E. WoodsDirectorJun 2010
Scott H. BiceDirectorJun 2010
Tina S. NovaDirectorJun 2010

About

American biopharmaceutical company.